3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
19
Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Bevacizumab
19
Paclitaxel
16
Carboplatin
12
pembrolizumab
11
liposomal doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Gemcitabine
8
olaparib
7
fludarabine
7
Topotecan
7
Magnetic Resonance Spectroscopy
7
Taxes
5
Immunoglobulin G
5
Fulvestrant
5
Disulfides
5
niraparib
4
Oxaliplatin
4
Nivolumab
4
Biopsy
4
trastuzumab deruxtecan
3
palbociclib
3
mirvetuximab soravtansine
3
aldesleukin
3
Leucovorin
3
Fluorouracil
3
1-dodecylpyridoxal
3
ulixertinib
2
nilotinib
2
ipatasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
enzalutamide
×
30 days
×
Clear all
No trials found.